|
| 2 April 2024 |
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Director/PDMR and PCA Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that it was notified on 28 March 2024 that on the same day Chris Meredith, who is a Director and PDMR, had sold 40,500 Ordinary Shares of 5p held on his behalf held in the name of Platform Securities Nominees Limited ("Nominee"), at a price of 196.15p per Ordinary Share.
On the same day, the Company was also informed that at the same time Individual Savings Accounts ("ISA's") held in the name of Chris Meredith purchased 5,160 Ordinary Shares of 5p, ISA's held in the name of Ingrid Meredith purchased 3,792 Ordinary Shares of 5p, ISA's in the name of Chris Meredith's PCA's purchased 26,472 Ordinary Shares of 5p and that Lifetime Individual Savings Accounts ("LISA's") held in the name of Chris Meredith's PCA's purchased 5,076 Ordinary Shares of 5p, all at a price of 196.2p per Ordinary Share.
The number of shares, and the beneficial ownership of the shares, held by Chris Meredith, Ingrid Meredith and his PCA's remains unchanged. These transactions are part of normalised tax planning.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a) | Name: Chris Meredith | ||||||
2. | Reason for the notification | ||||||
| a) | Position/status: Director | ||||||
| b) | Initial notification/Amendment: Initial Notification | ||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
| a) | Name: Advanced Medical Solutions Group plc | ||||||
| b) | LEI: 213800HJP6OWOSZI1L74 | ||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
| a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||||
| b) | Nature of the transactions: · Sale of 5,160 Ordinary Shares of 5p held in the name of the Nominee · Purchase of 5,160 Ordinary Shares of 5p into ISA's held in the name of Chris Meredith | ||||||
| c) | Price(s) and volume(s): Sale of shares:
| ||||||
| d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: 5,160 Aggregated price: 196.15p | ||||||
| e) | Date of the transaction: 28/03/2024 | ||||||
| f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a) | Name: Chris Meredith | ||||||
2. | Reason for the notification | ||||||
| a) | Position/status: Director | ||||||
| b) | Initial notification/Amendment: Initial Notification | ||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
| a) | Name: Advanced Medical Solutions Group plc | ||||||
| b) | LEI: 213800HJP6OWOSZI1L74 | ||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
| a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||||
| b) | Nature of the transactions: · Sale of 3,792 Ordinary Shares of 5p held in the name of the Nominee · Purchase of 3,792 Ordinary Shares of 5p into ISA's held in the name of Ingrid Meredith | ||||||
| c) | Price(s) and volume(s): Sale of shares:
| ||||||
| d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: 3,792 Aggregated price: 196.15p | ||||||
| e) | Date of the transaction: 28/03/2024 | ||||||
| f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a) | Name: Chris Meredith | ||||||
2. | Reason for the notification | ||||||
| a) | Position/status: Director | ||||||
| b) | Initial notification/Amendment: Initial Notification | ||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
| a) | Name: Advanced Medical Solutions Group plc | ||||||
| b) | LEI: 213800HJP6OWOSZI1L74 | ||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
| a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||||
| b) | Nature of the transactions: · Sale of 26,472 Ordinary Shares of 5p held in the name of the Nominee · Purchase of 26,472 Ordinary Shares of 5p into ISA's held in the name of Chris Meredith's PCA's | ||||||
| c) | Price(s) and volume(s): Sale of shares:
| ||||||
| d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: 26,472 Aggregated price: 196.15p | ||||||
| e) | Date of the transaction: 28/03/2024 | ||||||
| f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a) | Name: Chris Meredith | ||||||
2. | Reason for the notification | ||||||
| a) | Position/status: Director | ||||||
| b) | Initial notification/Amendment: Initial Notification | ||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
| a) | Name: Advanced Medical Solutions Group plc | ||||||
| b) | LEI: 213800HJP6OWOSZI1L74 | ||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
| a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||||
| b) | Nature of the transactions: · Sale of 5,076 Ordinary Shares of 5p held in the name of the Nominee · Purchase of 5,076 Ordinary Shares of 5p into LISA's held in the name of Chris Meredith's PCA's | ||||||
| c) | Price(s) and volume(s): Sale of shares:
| ||||||
| d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: 5,076 Aggregated price: 196.15p | ||||||
| e) | Date of the transaction: 28/03/2024 | ||||||
| f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
- End -
For further information, please visit www.admedsol.com or contact:
| Advanced Medical Solutions Group plc | Tel: +44 (0) 1606 545508 |
| Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer Michael King, Investor Relations | |
| |
|
| ICR Consilium | Tel: +44 (0) 20 3709 5700 |
| Mary-Jane Elliott / Lucy Featherstone | AMS@consilium-comms.com |
| | |
| Investec Bank PLC (NOMAD & Broker) | Tel: +44 (0) 20 7597 5970 |
| Gary Clarence / David Anderson | |
| | |
| HSBC Bank PLC (Broker) | Tel: 44 (0) 20 7991 8888 |
| Sam McLennan / Joe Weaving / Stephanie Cornish | |
About Advanced Medical Solutions Group plc - see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.
AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 900 employees. For more information, please see www.admedsol.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.